On July 9, 2026, an insider at Neurocrine Biosciences (NASDAQ: NBIX) made a significant stock sale. Delaet Ingrid, the Chief Regulatory Officer, sold 8,433 shares of Common Stock at a price of $178.72 per share. This transaction totaled approximately $1.51 million, leaving her with a direct ownership of 16,225 shares in the company.
Neurocrine Biosciences is a neuroscience-focused company that develops treatments for neurological and endocrine-related diseases. Its main product is Ingrezza, a treatment for a condition called tardive dyskinesia. Since its launch in 2017, Ingrezza has been the market leader as the first FDA-approved therapy of its kind.
The company's growth is supported by strong commercial performance. As highlighted by Zacks Investment Research, Neurocrine Biosciences is benefiting from rising sales of Ingrezza and the increasing use of another product, Crenessity. The company also expanded its portfolio by acquiring Soleno, which added the drug Vykat XR to its offerings.
Reflecting this positive momentum, Zacks Investment Research recently upgraded Neurocrine Biosciences to a Zacks Rank #1 (Strong Buy). This upgrade is based on growing optimism about the company's earnings prospects. The stock is currently trading at $180.55, with a total company value, or market capitalization, of approximately $18.15 billion.
Investors will have an opportunity to learn more about the company's financial health soon. Neurocrine Biosciences has announced a conference call and webcast to discuss its second-quarter 2026 financial results. The event is scheduled to take place on July 30, 2026.
